| | 477202-00-9 Basic information More.. |
| Product Name: | ipilimumab | | Synonyms: | ipilimumab;Ipilimumab (anti-CTLA-4);Ipilimubab;Research Grade Ipilimumab(DHD17201);BMS734016,MDX010,Ipilimumab,inhibit,BMS-734016,BMS 734016,Inhibitor,MDX 010,MDX-010;Research Grade Ipilimumab;Ipilimumab 5mg/ml | | CAS: | 477202-00-9 | | MF: | | | MW: | 0 | | EINECS: | | | Mol File: | Mol File |  |
Use
Ipilimumab is a CTLA-4 blocking antibody that was approved by the
U.S. FDA in March 2011 for the treatment of unresectable or metastatic
melanoma. Therefore, ipilimumab has an indirect effect on tumors that is
mediated through blockade of CTLA-4 negative signaling and
augmentation of T-cell activity. It is one of a handful of
immunostimulatory drugs (e.g., aldesleukin and interferon alfa-2b) now approved for cancer therapy.
- ipilimumab
-
- US $0.00-0.00 / g
- 2025-08-06
- CAS:477202-00-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100G
- Ipilimumab
-
- US $456.00-1060.00 / mg
- 2025-07-09
- CAS:477202-00-9
- Min. Order:
- Purity: 98.50%
- Supply Ability: 10g
- ipilimumab
-
- US $0.00 / g
- 2024-09-25
- CAS:477202-00-9
- Min. Order: 10g
- Purity: 98%
- Supply Ability: 50kg
|
|
477202-00-9
Recommend Suppliers |
|